1

Relatlimab: A Detailed Examination into BMS-986016 and its Prospects

1673516987432828
Relatlimab, formerly known as BMS-986016, represents a novel treatment approach in tumor approach, functioning as a targeted LAG-3 blocker. Its working principle centers around neutralizing the LAG-3 route, effectively https://www.targetmol.com/compound/relatlimab
Report this page

Comments

    HTML is allowed

Who Upvoted this Story